Transitioning to the 2021 Optimal Formulary for Antiretroviral Drugs for Children

Overview

Antiretroviral therapy (ART) optimization is a key pillar in the AIDSFree agenda to reach the goal of ensuring that 95% of all infants and children living with HIV known to have HIV have access to life-saving treatment. Despite progress in recent years to provide ART to almost 1 million infants and children living with HIV, attaining the third target of 95% viral suppression will remain an elusive goal without access to more effective treatment in age- and weight-appropriate formulations.

This policy brief outlines key considerations to facilitate effective transitions to more clinically appropriate regimens as optimal antiretroviral (ARV) drugs become available for infants and young children at the country level.